Results 91 to 100 of about 1,993 (117)

Therapeutic schemes in 177Lu and 90Y-PRRT: Radiobiological considerations

, 2017
BACKGROUND: The purpose of this work is to implement a radiobiological model to compare different treatment schedules for Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu and 90Y. The principal radiobiological quantities were studied as a function
Strigari, Lidia, Bodei, Lisa, D'Errico, Vincenzo, Cremonesi, Marta, Fioroni, Federica, Grassi, Elisa, Guerriero, Francesco, Botta, Francesca, Sarnelli, Anna, PAGANELLI, Giovanni, Ferrari, Mahila, Orecchia, Roberto   +11 more
core   +1 more source

A case report of enduring benefit of sequential PRRT in malignant insulinoma

EJNMMI Reports
We report the case of a 62-year-old woman diagnosed in 2015 with de novo metastatic malignant insulinoma. She presented severe hypoglycemia and was initially treated with somatostatin analogs, chemotherapy (capecitabine-temozolomide), and diazoxide, but ...
Cristina-An Wang Zhang, Natacha Driessens, Magdalena Mileva, Amélie Deleporte, Patrick Flamen, Ioannis Karfis   +5 more
doaj   +1 more source

Towards Effective Targeted Alpha Therapy for Neuroendocrine Tumours: A Review

Pharmaceuticals
This review article explores the evolving landscape of Molecular Radiotherapy (MRT), emphasizing Peptide Receptor Radionuclide Therapy (PRRT) for neuroendocrine tumours (NETs).
Paul M. D. Gape, Michael K. Schultz, Graeme J. Stasiuk, Samantha Y. A. Terry   +3 more
doaj   +1 more source

Is there a role for early SSTR-targeting PRRT in GEP-NET?

Purpose: Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues, such as [177Lu]Lu-DOTATATE, is approved as a second-line treatment for progressive, gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Piscopo, Leandra, Arco, Martina, Minutoli, Fabio, Bauckneht, Matteo, Burger, Irene A., Pagano, Benedetta, Fiorillo, Luca, Iagaru, Andrei, Berretta, Massimiliano, Curatolo, Sabrina, Auditore, Lucrezia, Ricciardello, Giorgia, Vinci, Sergio Lucio, Celesti, Greta, Amato, Ernesto, Piras, Antonio, Laudicella, Riccardo, Shariftabrizi, Ahmad   +17 more
core   +1 more source

Retrospective analysis of Peptide Receptor Radionuclide Therapy (PRRT) in Japanese patients with unresectable neuroendocrine tumor.

e16700 Background: Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogues is an innovative treatment for inoperable or metastasized, well/moderately differentiated, neuroendocrine tumors (NETs).
Ichikawa, Yasushi, Kobayashi, Noritoshi, Wild, Damian, Kaul, Felix   +3 more
core   +1 more source

PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT) AND THE PITUITARY: SAFETY AND EFFICACY

Peptide receptor radionuclide therapy (PRRT) is an emerging and promising targeted treatment for aggressive pituitary neuroendocrine tumours (PitNETs) and pituitary carcinomas refractory to conventional therapies.
Francesco Ferraù, Salvatore Cannavò, Elena Sofia Blanca, Carla Paola Costa   +3 more
core   +1 more source

Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs)

Rationale: Peptide receptor radionuclide therapy (PRRT) for the treatment of neuroendocrine tumors (NETs) has been explored for more than two decades, but there are only limited data on the treatment of NETs of unknown primary site (CUP-NETs). This study
Baum, Richard P., Zhang, Jingjing, Schuchardt, Christiane, Khong, Pek Lan, Wang, Peipei, Jakobsson, Vivianne, Zhao, Tianzhi   +6 more
core   +1 more source

Evaluation prognostischer Faktoren der PRRT bei neuroendokrinen Tumoren – der Weg zur individualisierten Therapie

EVALUATION PROGNOSTISCHER FAKTOREN DER PRRT BEI NEUROENDOKRINEN TUMOREN – DER WEG ZUR INDIVIDUALISIERTEN THERAPIE Evaluation prognostischer Faktoren der PRRT bei neuroendokrinen Tumoren – der Weg zur individualisierten Therapie / Wetz, Christoph (Rights
Wetz, Christoph
core  

Hematological toxicities following peptide receptorradionuclide therapy (PRRT) in neuroendocrine tumors –a retrospective single center analysis

Hintergrund: Die Peptidrezeptor-Radionuklidtherapie (PRRT) zielt auf denSomatostatinrezeptor (SSR) in neuroendokrinen Neoplasmen (NEN) ab undverwendet Somatostatinanaloga mit den Isotopen Yttrium oder Lutetium und derenionisierende Strahlung als Mittel ...
Ferreira Kienbacher, Sara Teresa
core  

Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate [PDF]

European Journal of Nuclear Medicine and Molecular Imaging, 2016
Purpose: After peptide receptor radionuclide therapy (PRRT), renal toxicity may occur, particular in PRRT with 90Y-labelled somatostatin analogues.
Guido Krenning, Mark Konijnenberg, Dik J Kwekkeboom   +2 more
exaly   +4 more sources